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Abstract
Purpose Thrombus perviousness has been associated with fa-
vorable functional outcome in acute ischemic stroke (AIS)
patients. Measuring thrombus perviousness on CTA may be
suboptimal due to potential delay in contrast agent arrival in
occluded arteries at the moment of imaging. Dynamic se-
quences acquired over time can potentially overcome this is-
sue. We investigate if dynamic CTA has added value in
assessing thrombus perviousness.
Methods Prospectively collected image data of AIS patients
with proven occlusion of the anterior or posterior circulation
with thin-slice multi-phase CTA (MCTA) and non-contrast
CT were co-registered (n = 221). Thrombus attenuation in-
crease (TAI; a perviousness measure) was measured for the
arterial, venous, and delayed phase of the MCTA and time-
invariant CTAs (TiCTA). Associations with favorable clinical
outcome (90-day mRS ≤ 2) were assessed using univariate
and multivariable regressions and calculating areas under re-
ceiver operating curves (AUC).
Results TAI determined from the arterial phase CTAwas su-
perior in the association with favorable outcome with
OR = 1.21 per 10 HU increase (95%CI 1.04–1.41, AUC
0.62, p = 0.014) compared to any other phase (venous
1.14(95%CI 1.01–1.30, AUC 0.58, p = 0.033), delayed
1.046(95%CI 0.919–1.19, AUC 0.53, p = 0.50)), and TiCTA
(1.15(95%CI 1.02–1.30, AUC 0.60, p = 0.022). In the multi-
variable model, only TAI on arterial phase was significantly
associated with favorable outcome (aOR 1.59, 95%CI 1.04–
2.43, p = 0.032).
Conclusion Association between TAI with functional out-
come was optimal on arterial-phase CTA such that dynamic
CTA imaging has no additional benefits in current thrombus
perviousness assessment, thereby suggesting that the delay of
contrast arrival at the clot is a key variable for patient func-
tional outcome.
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Introduction
Assessing thrombus characteristics on admission imaging
may assist in acute ischemic stroke (AIS) management [1].
Thrombus length, density, and burden assessed on acute im-
aging has been associated with patient functional outcome and
treatment success [2, 3]. Thrombus permeability is also con-
sidered to be associated with improved outcomes. Since the
permeability of thrombi cannot be assessed in standard radio-
logical imaging, derived metrics have been introduced such as
attenuation increase (TAI) and void fraction. To distinguish
the permeability from these derived measures, these charac-
teristics have been referred to as thrombus perviousness mea-
sures [1]. TAI compares thrombus attenuation on CTA with
NCCT and has been shown to be strongly associated with
intravenous plasminogen activator treatment success, favor-
able functional outcome, and admission deficit in AIS patients
[4, 5]. A potential drawback of this CTA-based measure is that
enhancement of arteries (and thrombus) on CTA is affected by
the timing of imaging [6]. In occluded arteries, with or without
a permeable thrombus, arterial filling proximal and distal to a
blood clot is delayed compared to the contralateral healthy
side. Therefore, thrombus permeability assessment may be
suboptimal if the CTA is acquired before contrast arrival in
the occluded artery. A dynamically acquired CTA has the
potential to resolve this timing issue. Furthermore, dynamical-
ly acquired CTA allows the generation of a time-invariant
CTA in the form of a temporal maximum intensity profile
(TiCTA) [6–10]. Recently, a multiphase CTA (MCTA) imag-
ing protocol was developed in which multiple temporal image
data sets are generated with a high spatial resolution, which
also allows the generation of TiCTA [11].We hypothesize that
TAI imaged with MCTA is potentially stronger associated
with good functional outcome and admission deficit in pa-
tients with AIS than a Bsnapshot^ CTA.
Material and methods
Patient inclusion
We retrospectively collected clinical and image data of 299
patients with proven occlusion of the anterior and posterior
circulation from the BMeasuring Collaterals With Multi-phase
CT Angiography in Patients With Ischemic Stroke^ (PRove-
IT) trial population (protocol at https://clinicaltrials.gov/ct2/
show/NCT02184936). Patient exclusion criteria for this
substudy were absence of functional outcome data (n = 5),
incomplete axial coverage (n = 6), excessive noise (n = 2),
movement (n = 45) and cerebrospinal fluid shunt (n = 1)
induced artifacts, and insufficient contrast on the arterial-
phase CTA to accurately perform the thrombus measurements
(n = 8). This resulted in 233 patients that were included in this
study. The Conjoint Health Research Ethics Board approved
the study.
Imaging
In the PRove-IT study population, all patients underwent stan-
dard unenhanced CT with 5-mm section thickness followed
by a 0.625-mm section thickness multiphase CT angiography
(Figure 1) [11]. MCTA techniques generate time-resolved ce-
rebral angiograms of brain vasculature from the skull base to
the vertex in three phases after 80 mL contrast material injec-
tion (68% ioversol, Optiray 320; Mallinckrodt, St Louis, Mo)
at a rate of 5 mL/s and followed by a 50-mL normal saline
chase at a rate of 6 mL/s. The mean estimated effective dose
was 5.0 ± 0.5 mSv for the first phase CTA and 1.0 ± 0.5 mSv
per additional phase of the multiphase CT angiography. The
first phase covers the aortic arch to the vertex and is timed to
scan during the peak arterial phase in a healthy brain (bolus
monitoring triggering). The next two phases are performed
from the skull base to the vertex without injection of new
contrast about 7–9 s apart as follow: the first delayed image
acquisition starts after the arrival of contrast in the descending
aorta. The second delayed imaging starts in the late venous
phase. With this acquisition protocol, we obtain an image for
three phases, which will be referred to as arterial, venous, and
delayed phase respectively in the remainder of this
manuscript.
From the MCTA data, a TiCTAwas generated as a tempo-
ral maximum intensity projection of the three phases [9]. To
avoid artifacts due to motion between the acquisition phases,
each phase was co-registered [12] with the arterial phase using
the registration software Elastix [13].
Thrombus perviousness
The TAI measurements were performed as previously de-
scribed [14]: Three spherical regions of interests
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(radius = 1 mm) were placed in the thrombus on the arterial-
phase CTA. The placement of the region of interests was sup-
ported by a custom-developed interface in Mevislab [15] in
which NCCTand the arterial phase CTAwere simultaneously
displayed. The assessments were performed by one of the two
trained raters (ES or KT) and an expert rater (CM) if the other
raters were unsure of their assessment due to a poor image
enhancement. Initially, the arterial, the venous, and the de-
layed phase CTAs and NCCT images were co-registered with
Elastix [13] using a rigid registration method. If the automated
registration was suboptimal, a manual correction was per-
formed (ES) using a toolbox available in Mevislab [15].
Using the co-registered images, the manually placed regions
of interests in the arterial-phase CTA were automatically
projected on all other CT images.
The mean attenuation of the manually placed regions of
interests were used to calculate four TAI measures: the
TAIArterial, TAIVenous, TAIDelayed, and TAITiCTA by subtracting
the thrombus attenuation on NCCT from the attenuation on
the arterial, venous, and delayed phase CTAs and TiCTA,
respectively.
Statistical analysis
The association of the four TAI measures with functional out-
come was assessed by performing univariate regression anal-
ysis. Strength of these associations were compared using the
area under the receiver operating characteristic curve.
Favorable outcome was defined as a score of 2 or less on the
modified Rankin Scale (mRS) at 90 days. Functional deficit
on admission was scored with the National Institutes of Health
Stroke Scale (NIHSS), which was considered continuous in
our analyses.
Data is presented with mean and standard deviation for
normally distributed values or with median and interquartile
range (IQR) otherwise. Normality of the distributions was
assessed using the Shapiro-Wilk test. Categorical and ordinal
data were presented using count and proportions. TAI outliers
(n = 10) were eliminated using the Tukey outlier filter method
[16]. Differences between the four TAI measures were
assessed using pairwise comparisons (the Student test or the
Wilcoxon signed-rank test).
Association of TAI with favorable functional outcome
TAI differences between patients with favorable and unfavor-
able outcome were assessed using the Kruskal–Wallis test.
The odds ratio (OR) with 95% confidence intervals (95%CI)
to favorable outcome per 10 HU increase in TAI were calcu-
lated using univariate logistic regressions. Models were com-
pared using information theory approaches by calculating the
Akaike information criterion (AIC) and Bayesian information
criterion (BIC).
Association of TAI with admission deficit
Spearman’s correlation coefficient and the fit of the regression
R [2] were calculated to assess the association between TAI
measures and baseline NIHSS. Linear regression models de-
scribing the association between the four TAI measures and
baseline NIHSS were compared using AIC and BIC.
Fig. 1 Graphical illustration of the non-contrast and multiphase CT
angiography imaging protocol. From left to right: all patients underwent
standard non-contrast CT (5-mm section thickness) followed by a
multiphase CT angiography (0.625-mm section thickness). The
multiphase CT angiography is performed in three phases after 80 mL
contrast material injection without reinjections. The first phase: the
Barterial phase^ is timed to occur during the peak arterial phase and is
triggered by bolus monitoring. The next two, the BVenous phase^ and the
BDelayed phase^ are performed, the acquisition starts 7–9 s apart after the
arrival of contrast to the descending aorta. Coverage of the non-contrast
CT and of the venous-phase and delayed-phase CT angiography (CTA)
are from the skull base to the vertex. The arterial-phase CTA covers the
aortic arch to the vertex
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Multivariable analysis
Baseline clinical variables with statistically significant as-
sociations with favorable outcome and TAI were included
in a multivariable logistic regression analysis. Association
of baseline clinical variables with favorable outcome was
evaluated using logistic regression. The assessment of the
association of baseline clinical variables with the TAI mea-
sures was performed using one-way Kruskal–Wallis
ANOVA for ordinal variables, Spearman’s correlation co-
efficient for non-parametrically distributed variables, fit of
the regression R [2] for parametrically distributed
Table 1 TAI measures distributed for baseline clinical data and their associations with continuous clinical baseline and outcome variables
Dichotomized and ordinal variables
n (%) TAI median(IQR) in HU
Arterial-phase Venous-phase Delayed-phase TiCTA
All patients 221(100%) 36.7(28.0–48.5) 35(26.6–50.7) 30.1(20.2–41.6) 50.5(40.3–70.1)
Sex Female 111(50.2%) 39.7(30.7–52.9) 37.1(29.5–51.9) 31.4(22.4–43.6) 53.2(43.4–72.1)
Male 110(49.8%) 34.1(25.3–44.8) 33.4(24.7–45.9) 27.1(19.8–39.9) 47.7(37.9–64.4)
Occlusion location ICA 14(6.3%) 29.9(21.2–37.9) 35.6(21.7–51.6) 22.1(16.8–41.5) 45.2(35.1–77.6)
M1 94(42.5%) 34.9(26.0–45.4) 34.4(26.9–48.3) 31.1(22.4–44.1) 49.0(39.5–69.8)
M2 67(30.3%) 38.4(30.9–52.9) 39.1(28.1–58.6) 33.5(22.7–49.0) 56.0(43.1–73.3)
M3 and M4 18(8.1%) 38.8(33.1–56.0) 33.4(23.0–64.6) 23.4(16.8–34.3) 48.5(38.9–78.5)
Basilar 6(2.7%) 15.9(8.2–50.5) 13.6(7.3–21.6) 10.9(8.6–13.1) 26.3(23.6–56.1)
PCA 17(7.7%) 43.9(33.4–61.7) 38.0 (30.9–43.0) 23.8(16.9–34.0) 51.6(47.5–67.9)
ACA 5(2.3%) 41.5(35.2–41.5) 28.4(21.0–32.7) 34.4(10.0–36.9) 49.8(44.5–50.7)
Treated with anithrombolitics no 159(73.3%) 35.1(25.3–44.9) 34.2(25.6–47.7) 28.4(19.0–41.6) 49.4(38.1–66.3)
yes 58(26.7%) 42.1(31.3–57.8) 36.6(28.5–71.7) 33.2(23.1–45.4) 56.1(43.8–80.0)
Treatment decision None 49(22.3%) 41.3(31.2–57.5) 37.6(32.2–64.6) 33.0(23.1–40.5) 54.0(43.9–78.5)
IV-TPA 82(37.3%) 37.8(27.8–48.1) 34.5(26.9–51.1) 29.5(20.6–42.7) 51.4(38.9–68.7)
IA-TPA 25(11.4%) 33.9(29.4–42.8) 35.6(26.7–65.9) 26.6(20.2–50.7) 47.1(38.4–81.6)
IV + IA-TPA 58(26.4%) 34.8(24.2–42.8) 33.8(25.4–42.4) 28.6(17.9–41.6) 47.1(38.3–57.9)
Tenecteplase 6(2.7%) 40.3(32.7–43.9) 35.9(25.8–42.4) 27.1(15.9–41.4) 49.9(40.9–54.2)
mRS score 0 40(18.1%) 38.0(26.5–47.1) 36.3(24.2–51.7) 25.0(18.3–46.2) 50.9(38.4–77.9)
1 48(21.7%) 40.0(31.5–57.7) 34.5(27.6–53.2) 34.3(20.3–50.6) 57.7(45.5–72.9)
2 43(19.5%) 41.5(30.9–52.8) 37.1(29.5–58.6) 28.6(20.7–43.4) 49.7(43.4–72.4)
3 24(10.9%) 34.8(26.9–57.0) 34.6(24.7–45.7) 30.8(22.4–42.0) 52.1(36.1–78.4)
4 25(11.3%) 30.9(24.0–37.5) 33.5(26.0–41.4) 29.4(16.6–37.6) 45.5(38.1–64.4)
5 6(2.7%) 36.2(29.7–47.0) 40.6(28.8–53.0) 32.6(30.3–34.8) 52.1(39.9–60.0)
6 35(15.8%) 33.2(20.9–42.2) 33.4(20.7–41.9) 26.4(19.8–40.5) 43.9(31.1–56.0)
Functional outcome Unfavorable 90(40.7%) 33.3(24.7–42.8) 33.5(24.7–44.0) 30.3(20.2–39.7) 46.1(36.8–63.4)
Favorable 131(59.3%) 39.5(30.9–51.0) 35.6(27.6–54.0) 30.0(20.2–44.5) 52.7(42.6–73.3)
Continuous variables
Unit Median(IQR) Spearman’s rho (linear regression beta’s per 10HU)
Arterial phase Venous phase Delayed phase TiCTA
Age Year 73 (62–80) 0 (.013) .133* (.046) .162* (.082) .089 (.037)
Hematocrit % 42 (38–45) .009 (0) −.034 (0) −.026 (0) −.006 (0)
NIHSS Score 12 (6–19) −.229**(−.087) −.099 (−.033) −.036 (−.01) −.161*(−.044)
mRS score: 0, no symptoms at all; 1, no significant disability despite symptoms; 2, slight disability; 3, moderate disability; 4, moderately severe
disability; 5, severe disability; 6, dead
TAI thrombus attenuation increase, HU Hounsfield unit, IQR interquartile range, TiCTA time invariant computed tomography angiography, IV-rtPA
intravenous recombinant tissue-type plasminogen activator treatment, IA-TPA intra-arterial recombinant tissue-type plasminogen activator treatment,
mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, ACA anterior cerebral artery, ICA intracranial cerebral artery, M1
sphenoidal segment of the middle cerebral artery,M2 insular segment of the middle cerebral artery,M3 opercular segment of the middle cerebral artery,
M4 cortical segment of the middle cerebral artery, PCA posterior cerebral artery
**Correlation is significant at the 0.01 level; *Correlation is significant at the 0.05 level
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variables, and the Wilcoxon signed-rank test for dichoto-
mized data.
Statistical significance was set to a p value < 0.05 for all
analyses. Analyses were performed using IBM SPSS
Statistics software, version 21.0 (IBM Corporation, Armonk,
NY, USA).
Results
TAI measures distributed for baseline and outcome character-
istics are presented in Table 1. The average age was 71 (± 13)
years, 51% (121) of the patients were female and the median
admission National Institutes of Health Stroke Scale (NIHSS)
was 13 (IQR 6–19). Themajority (59.1%) of the patients had a
favorable functional outcome. Nine (3.8%) patients required
additional manual correction of the image registration.
Median TAIs were 37 (IQR 28–49), 35 (IQR 27–51), 30
(IQR 20–42), and 50 (IQR 40–70) HU respectively for the
arterial, the venous, and the delayed phase and the TiCTA.
All but the TAI from the arterial and the venous phase CTAs
were significantly different. Associations of baseline charac-
teristics with functional outcome are presented in Table 2.
TAI association with clinical outcome
The TAI measures were significantly different between pa-
tients with favorable and unfavorable functional outcome for
the arterial-phase CTA, the venous-phase CTA, and TiCTA
(p = 0.003, p = 0.044, and p = 0.011, respectively). The TAI
distributions per outcome group are shown in Fig. 2. In the
univariate models, the ORs (95% CI, p) for a favorable
Table 2 Baseline and follow-up clinical data, descriptive analysis and their associations with Functional outcome
Dichotomized and ordinal variables
All patients n (%) Functional outcome Association with favorable outcome
Favorable n (%) Unfavorable n (%) OR (95%CI) p
All patients 221(100%) 131(59.3%) 90(40.7%)
Sex Female 111(50.2%) 64(48.9%) 47(52.2%) 0.6(0.3–1.3) 0.20
Male 110(49.8%) 67(51.1%) 43(47.8%)
Occlusion location ICA 14(6.3%) 8(6.1%) 6(6.7%) 4.6(0.4–51.0) 0.21
M1 94(42.5%) 45(34.4%) 49(54.4%) 4.1(0.5–31.9) 0.18
M2 67(30.3%) 45(34.4%) 22(24.4%) 3.3(0.4–25.0) 0.25
M3 and M4 18(8.1%) 16(12.2%) 2(2.2%) 7.0(0.6–87.3) 0.13
Basilar 6(2.7%) 4(3.1%) 2(2.2%) 2.7(0.1–51.3) 0.51
PCA 17(7.7%) 11(8.4%) 6(6.7%) 2.7(0.3–26.6) 0.39
ACA 5(2.3%) 2(1.5%) 3(3.3%)
Treated with antithrombolitics no 159(73.3%) 92(71.3%) 67(76.1%) 0.4(0.1–2.0) 0.29
yes 58(26.7%) 37(28.7%) 21(23.9%)
Treatment None 49(22.3%) 30(22.9%) 19(21.3%) 0.3(0.0–5.6) 0.44
IV-TPA 82(37.3%) 47(35.9%) 35(39.3%) 1.4(0.1–15.6) 0.78
IA-TPA 25(11.4%) 13(9.9%) 12(13.5%) 1.7(0.1–22.2) 0.69
IV+IA-TPA 58(26.4%) 36(27.5%) 22(24.7%) 4.6(0.4–59.2) 0.24
Tenecteplase 6(2.7%) 5(3.8%) 1(1.1%)
Continuous variables
Unit Median(IQR) Functional outcome Association with favorable outcome
Favorable Unfavorable OR (95%CI) p
Age Year 73 (62–80) 71(58–77) 77(69–84) 0.96(0.93–0.98) 0.002
Hematocrit % 0.42 (0.38–0.45) 0.42(0.40–0.45) 0.41(0.36–0.45) 11.2(0.0–6405.7) 0.46
NIHSS score 12 (6–19) 9(5–15) 18(12–23) 0.82(0.77–0.88) <0.001
TAI thrombus attenuation increase,HUHounsfield unit,OR odds ratio, CI confidence interval, p significance value, IQR interquartile range, TiCTA time
invariant computed tomography angiography, IV-rtPA intravenous recombinant tissue-type plasminogen activator treatment, IA-TPA intra-arterial
recombinant tissue-type plasminogen activator treatment; mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, ACA anterior
cerebral artery, ICA intracranial cerebral artery,M1 sphenoidal segment of the middle cerebral artery,M2 insular segment of the middle cerebral artery,
M3 opercular segment of the middle cerebral artery, M4 cortical segment of the middle cerebral artery, PCA posterior cerebral artery mRS score: 0, no
symptoms at all; 1, no significant disability despite symptoms; 2, slight disability; 3, moderate disability; 4, moderately severe disability; 5, severe
disability; 6, dead; and for italic values, p is significant at the 0.05 level
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outcome per 10 HU increase in TAIs were 1.21 (95%CI 1.04–
1.41, p = 0.014) for TAIArterial, 1.14 (95%CI 1.01–1.30,
p = 0.033) for TAIVenous, and 1.15 (95%CI 1.02–1.30,
p = 0.022) for TAITiCTA. There was no significant association
between TAIDelayed and favorable outcome. The AUCs of the
receiver operating curves were 0.62, 0.58, 0.53, and 0.60,
respectively for the arterial phase, the venous phase, the de-
layed phase, and the TiCTA. The AIC and BIC were both
lowest for TAIArterial (Table 3).
TAI association with admission deficit
Baseline NIHSS was significantly correlated with TAIArterial
and TAITiCTAwith a Spearman’s correlation coefficient and R
[2] of − .229 (.045) and − .161(.044), respectively (Table 1).
From the linear regression, the beta coefficients were −0.87
(95%CI − 1.40 to − 0.34, p = 0.002) and − 0.44 (95%CI − 0.87
to − 0.01, p = 0.044) per 10 HU increase of TAIArterial and
TAITiCTA, respectively. There was no significant association
between TAIDelayed and TAIVenous and baseline NIHSS. The
AIC and BIC were lowest for TAIArterial (Table 3).
Multivariable analysis
Of all clinical variables, only age and baseline NIHSS were
significantly associated with favorable outcome (Table 2).
Baseline NIHSS was significantly correlated with
TAIArterial and TAITiCTA while age was borderline signifi-
cantly correlated with TAIVenous phase and TAIDelayed
(Table 1). These parameters and their corresponding inter-
action terms were added in all subsequent modeling. In
multivariable modeling including TAIArterial, age, and
baseline NIHSS, only age and TAI were independently
associated with favorable outcome. In the TiCTA multivar-
iable model (including age and baseline NIHSS), only age
and NIHSS were independently associated with favorable
outcome. In both the delay phase and venous phase CTA
multivariable models, only baseline NIHSS was signifi-
cant. The AIC and BIC were the lowest for the multivari-
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Fig. 2 Boxplot of the TAI measures on arterial-phase, venous-phase,
delayed-phase CTA, and on TiCTA for patients with unfavorable
(mRS > 2) and favorable (mRS ≤ 2) functional outcome. There were
statistically significant differences in the distributions of perviousness
between the two groups for the TAI assessed on arterial-phase, venous-
phase, and on TiCTA (Kruskal–Wallis Test). HU indicates Hounsfield
Unit; CTA, computed tomography angiography; TiCTA, time invariant
computed tomography angiography; p, significance value; mRS,
modified Rankin Scale; mRS score: 0, no symptoms at all; 1, no
significant disability despite symptoms; 2, slight disability; 3, moderate
disability; 4, moderately severe disability; 5, severe disability; 6, dead
Table 3 Association of TAI measures with outcomes using logistic regression analysis receiver operating curve analysis, linear regression and Akaike
and Bayesian information criterion
Clinical outcome Admission deficit
Univariate logistic regression analysis Linear regression
10 HU increase of TAI OR (95% CI) p AUC AIC BIC B (95% CI) p AIC BIC
Arterial phase 1.21(1.041–1.414) 0.01 0.62 296.1 302.9 −0.87(−1.4 to − 0.34) 0.002 903.0 909.7
Venous phase 1.148(1.011–1.303) 0.03 0.58 297.8 304.6 −0.33(−0.78 to 0.11) 0.139 910.9 917.7
Delayed phase 1.046(0.919–1.19) 0.50 0.53 302.3 309.1 −0.10(−0.59 to 0.39) 0.681 913.0 919.7
TiCTA 1.153(1.021–1.301) 0.02 0.60 297.0 303.8 −0.44(−0.87 to − 0.01) 0.044 909.0 915.8
TAI thrombus attenuation increase, OR odds ratio, aOR adjusted odds ratio, CI confidence interval, B linear regression coeficient, AUC area under the
curve, AIC Akaike information criterion, BIC Bayesian information criterion, p significance value,HUHounsfield unit, TiCTA time invariant computed
tomography angiography; and italic p is significant at the 0.05 level
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Discussion
This study validates findings from our previous studies that
thrombus perviousness is a significant independent predictor
of clinical outcome in patients with acute ischemic stroke.
Interestingly, our analysis also shows that thrombus pervious-
ness assessment on multiphase CTA either on late phases or
by creating a temporal maximum intensity projection does not
improve the ability to predict clinical outcome at 90 days or
clinical deficit on admission when compared to arterial single-
phase CTA.
The relation of TAI with functional outcome has been
shown in two other populations in previous studies [4, 5].
Although we found similar associations, the median throm-
bus attenuation increase we measured was much higher
than previously reported. Moreover, the patient outcome
in this population is better compared to the Multicenter
Randomized Clinical trial of Endovascular treatment of
acute ischemic stroke in the Netherlands (MR CLEAN)
and Dutch Acute Stroke Study (DUST) populations. The
higher TAI could be originated from the contrast agent
used, or from the voltage of the X-ray tube. However, these
potential sources of TAI measurement bias have been pre-
viously studied and have shown not to significantly influ-
ence on the perviousness measures in that population of
that study [4]. The higher TAI in this study could also be
because of the use of 5-mm slice thickness NCCT instead
of thin slice NCCTs. Previous studies had assessed TAI on
< 2.5 mm reconstruction NCCTs. Partial volume effect in
thick slice reconstructions can reduce thrombus attenuation
values , thereby resul t ing in higher TAI values .
Nonetheless, our analysis shows that the methodology of
measurement of TAI and its ability to predict clinical out-
comes are robust across varying NCCT slice thickness.
As previously found [5], in this study, patients with a high
TAI have lower baseline NIHSS. This may be because pervi-
ous thrombi allow occult anterograde flow to some degree,
which may result in less severe ischemia in affected brain
[17]. It was also previously shown [4] that despite failure to
recanalize, patients with a permeable thrombus were also as-
sociated with favorable functional deficits on follow-up.
Venous-phase CTA and TiCTA are conceptually better
at visualizing delayed flow through collaterals [6, 11]. It is
therefore intuitive to assume that these delayed or time
resolved images may also be better at detecting thrombus
perviousness. Nonetheless, our analysis shows that TAI
measured in the arterial phase is better associated with
clinical state. In our opinion, an arterial-phase TAI grasps
highly permeable thrombus with fast blood flow in con-
trary to venous or delayed phases that would grasp delayed
arrival of contrast to the clot due to less permeable thrombi
or stagnant flow. However, early antegrade flow is a
known important predictor of clinical outcome [10, 17,
18]. Therefore, TiCTA only reflects the total thrombus per-
viousness whilst overlooking if the flow is early or late.
Such that, this ability to discriminate fast and medium
flowing blood through a permeable thrombus from multi-
phase CTA could be useful as it may influence the likeli-
hood of recanalization (spontaneous, with intravenous re-
combinant tissue-type plasminogen activator treatment
(IV-rtPA) treatment [5] or with mechanical debunking
[19]) and may be linked to the functional clot length and
therefore hence an associated chance of filling of perfora-
tors and other collateral pathways. We did not test the as-
sociation of thrombus perviousness with early reperfusion
because of heterogeneity of treatment offered and the lim-
ited size for the potential patient subgroups; nonetheless,
we have shown robust association with relevant clinical
outcomes.
Our study has some limitations. Observers placed the re-
gion of interest on one single-phase series rather than on all
phases separately. This may have resulted in inaccuracies in
the region of interest placement of other phases due to subop-
timal registration. However, all registrations were checked for
Table 4 Multivariable regression
analysis of the association of TAI
measures with favorable
functional outcome
10 HU increase of TAI Regression analysis AIC BIC
Model 1 Model 2
aOR (95% CI) p aOR ((95% CI) p
Arterial phase 1.589(1.04–2.428) 0.03 – – 234.7 251.7
Venous phase – – 1.423(0.559–3.621) 0.59 234.1 251.1
Delayed phase – – 1.363(0.437–4.248) 0.46 238.0 255.0
TiCTA 1.216(0.87–1.7) 0.25 – – 235.0 252.0
Model 1: Age, NIHSS, TAI and TAI*NIHSS; Model 2: Age, NIHSS,TAI and TAI*Age; and italic p is significant
at the 0.05 level
TAI thrombus attenuation increase,OR odds ratio, aOR adjusted odds ratio, CI confidence interval, p significance
value, NIHSS National Institutes of Health Stroke Scale, HU Hounsfield unit, TiCTA time invariant computed
tomography angiography, AIC Akaike information criterion, BIC Bayesian information criterion
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accuracy and corrected if necessary. Furthermore, as men-
tioned above, the thick slice NCCT used in the assessment
may have biased the perviousness measurements. Finally,
the measurements have been performed by only a single ob-
server per patient. Ideally, all cases should have been reviewed
by both users to assess the interobserver variation. However, it
was shown that placing three regions of interest is less sensi-
tive to observer variability [14].
Recent guidelines encourage the development of accurate
imaging biomarkers to select patients that will likely benefit
from intravenous or from intra-arterial treatment [20].
Thrombus permeability is a potentially important biomarker
that can be used for patient stratification in a clinical acute
setting [4]. This study suggests that TAI measured on
arterial-phase CTA alone is a robust predictor of thrombus
permeability in patients with acute ischemic stroke.
Conclusion
Surprisingly, dynamic CTA imaging has little additional ben-
efits in the current assessment of thrombus perviousness. Time
invariant CTA was not stronger associated with functional
outcome compared to conventional arterial-phase CTA. This
suggests that conventional arterial phase CTA is sufficient in
the assessment of the thrombi perviousness and that the speed
of contrast passage is important for the functional outcome of
patients with acute ischemic stroke.
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